The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company released an investor presentation, revealing strong top-line growth in 2025. Group revenue jumping 56% year-on-year to US$804 million, and underlying profitability supported by a positive cash balance of US$142 million.
Image source: Getty Images
What did Telix Pharmaceuticals report?
- Group revenue of US$804 million, up 56% from FY25, meeting upgraded guidance
- Precision Medicine revenue rose 22% year on year to US$622 million
- RLS Radiopharmacies contributed US$170 million in revenue after acquisition
- Group EBITDA of US$40 million
- Positive cash balance of US$142 million as at year end
- Investment of over US$500 million across R&D and strategic initiatives
What else do investors need to know?
Telix's commercial momentum continues, with Q1 2026 unaudited group revenue climbing 11% quarter on quarter to US$230 million. The company is progressing multiple clinical-stage assets, with four therapies now in pivotal or phase 3 trials targeting prostate, kidney, and brain cancers.
Regulatory advances have been made for new products, including Pixclara (TLX101-Px), which has a US FDA target decision date of 11 September 2026, and Illuccix accepted for review in China. Telix has also signed a new global collaboration with Regeneron to co-develop radiopharmaceutical therapies for solid tumours, bringing in US$40 million upfront with potential for further milestone payments.
What's next for Telix Pharmaceuticals?
Looking ahead, Telix has issued FY26 revenue guidance in the range of US$950 million to US$970 million, with continued growth expected in its Precision Medicine segment and full-year contributions from recent acquisitions. R&D investment is targeted between US$200 million and US$240 million, mainly focused on advancing late-stage therapeutics and delivery of clinical milestones.
The company aims to launch new precision imaging and therapy products, complete key clinical trials, and enhance its manufacturing capacity with projects underway in Europe and Japan. Management emphasises reinvesting earnings to support long-term sustainable growth and innovation in radiopharma.
Telix Pharmaceuticals share price snapshot
Over the past 12 months, Telix shares have risen 41%, underperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.
